ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors

Tue Jan 22, 2013 9:00am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130122:nBw225566a

SAN DIEGO--(Business Wire)--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused
on innovative treatments that address unmet medical needs in neurological and
related central nervous system disorders,today announced the election of Stephen
R. Biggar, M.D., Ph.D., to its board of directors. Dr. Biggar will fill a
vacancy on ACADIA`s board and serve as a Class II director. The terms of the
Class II directors will expire at the annual meeting of stockholders in 2015. 

"This is a particularly exciting time to join the ACADIA board following the
highly successful results from the pivotal Phase III Parkinson`s disease
psychosis trial with pimavanserin," said Dr. Biggar. "I share in ACADIA`s
enthusiasm and belief that pimavanserin has the potential to transform the
treatment landscape for patients suffering from this serious disorder and may
also offer an improved therapy option for a broader range of neuropsychiatric
disorders. Following the recent financing, which raised $86 million, ACADIA has
a solid foundation for building the full potential of pimavanserin. I look
forward to being a part of the ACADIA team as we work to develop and
commercialize pimavanserin and other potential new drugs that may improve the
lives of patients." 

Dr. Biggar serves as a Partner at Baker Brothers Investments, a fund management
company focused on long-term investments in life-sciences companies. From April
2002 to October 2006, he served as a Principal with Baker Brothers Investments
which he had joined as an Associate in April 2000. Prior to joining Baker
Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford
University and received a B.S. in Genetics from the University of Rochester. Dr.
Biggar also serves as a director for Synageva BioPharma Corp., a publicly traded
biotechnology company. 

"We are delighted that Steve has joined ACADIA`s board," said Uli Hacksell,
Ph.D., ACADIA`s Chief Executive Officer. "His extensive experience as an
investor in a wide range of biotechnology companies together with his medical
and scientific training will provide our board with a unique perspective and
enhance our collective experience." 

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a potential first-in-class treatment for
Parkinson's disease psychosis. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced
preclinical programs directed at Parkinson`s disease and other neurological
disorders. All product candidates are small molecules that emanate from
discoveries made at ACADIA. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can subscribe to
receive email alerts. 

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements include but are not limited to
statements related to the progress and timing of ACADIA`s drug discovery and
development programs, either alone or with a partner, and the clinical benefits
to be derived from ACADIA`s product candidates, in each case including
pimavanserin. In particular, forward-looking statements include statements
regarding the impact of ACADIA`s recent financing and the potential for
pimavanserin to transform the treatment landscape for Parkinson`s disease
psychosis and to be an improved therapy for a broader range of neuropsychiatric
disorders. These statements are only predictions based on current information
and expectations and involve a number of risks and uncertainties. Actual events
or results may differ materially from those projected in any of such statements
due to various factors, including the risks and uncertainties inherent in drug
discovery, development and commercialization, and collaborations with others,
and the fact that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors, please refer
to ACADIA`s annual report on Form 10-K for the year ended December 31, 2011 as
well as ACADIA`s subsequent filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made under
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. All forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or update
this press release to reflect events or circumstances after the date hereof,
except as required by law.

ACADIA Pharmaceuticals Inc.
Uli Hacksell, Ph.D., Chief Executive Officer
Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief
Business Officer
858-558-2871

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.